The global tangential flow filtration market is expected to generate $3,667.2 million revenue by 2030, advancing at a CAGR of 12.8% during 2021–2030. The major factors influencing the market growth include the rising demand for biopharmaceutical products due to their fewer side effects compared to conventional drugs, the surging preference for targeted therapies and personalized treatment, and the increasing research and development investment by biotechnology companies. For instance, the total number of clinical trials across the globe increased by approximately 3% CAGR during 2010–2021.
Moreover, there has been an increase in the number of emerging biopharma companies (EBPs) over the years, which accounted for more than 60% of the molecules in the research and development pipeline, as of 2021, and they filed for FDA approvals for more than 75% of the drugs originated in 2021. Furthermore, the spread of the COVID-19 virus causing the pandemic situation propelled the demand for TFF systems, which are largely used in the R&D and manufacturing of COVID-19 vaccines.
Single-use tangential flow filtration systems are widely used in biomanufacturing facilities to reduce labor costs and water usage for the cleaning of filters, and these systems are cost-effective as compared to reusable TFF systems and membrane filters. Also, these allow the preparation of protein-drug conjugates with the help of radioisotopes and toxic chemicals. Further, advances in single-use systems, flow-through chromatography, and single-pass tangential flow filtering have enabled integrated continuous downstream processing at labs or pilot scales.
The APAC region holds the third position, in terms of revenue contribution, in the tangential flow filtration market, and the regional market is expected to witness the highest CAGR, of 13.1%, during the forecast period. This is because pharmaceutical companies, especially biomanufacturing companies, are preferring to set up their manufacturing bases in countries such as India, Singapore, South Korea, China, and Australia, among others.
Currently, India and China together account for more than 15% of the global biomanufacturing capacity. Both countries hold a major share in sectors such as biosimilar, novel biological drugs, specialty pharmaceuticals, and vaccine manufacturing, among others. Moreover, government policies in both countries are also promoting the growth of the market. For instance, the ‘Make in India’ initiative and the ‘National Biopharma Mission’ scheme were started by the Government of India for domestic suppliers.
In recent years, biomanufacturing companies have been expanding their production capacity, resulting in the increasing use of tangential flow filtration systems for the separation of biomolecules. For instance, in November 2021, BioCina opened a biologics manufacturing facility in Adelaide, Australia, which houses tangential flow filtration systems for downstream purification and bulk filling along with chromatography skids and columns, among other equipment, for providing a wide range of clinical supply services.
Moreover, major companies have been launching new products to remain competitive in the market. For instance, Pall Corporation launched the Minimate EVO TFF system, in July 2021, for simplifying laboratory-scale concentration, desalting, and buffer exchange workflows.
Major players operating in the tangential flow filtration market include Merck KGaA, Danaher Corporation, Sartorius AG, Parker-Hannifin Corporation, Repligen Corporation, Alfa Laval Corporate AB, ANDRITZ, Meissner Filtration Products Inc., GE Healthcare, and Novasep.